Phase 2 Clinical Study in Major Depressive Disorder Expected to Commence at NIH in 3Q 2015 SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 07/01/15 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative product

Similar to Ketamine, AV-101 Has a Fundamentally Novel Mechanism of Action Compared to All Approved Antidepressants SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 02/17/15 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company developing innovative medicine for

Yale Depression Expert to Advise on Late-Stage Development of Orally-Active AV-101 for Major Depressive Disorder SAN FRANCISCO, CA -- (Marketwired) -- 02/05/15 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company developing innovative medicine for depression and

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/17/14 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company focused on innovative medicine for depression, cancer and diseases and disorders involving the central nervous system (CNS), has signed a Letter of Intent to

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 08/19/14 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying pluripotent stem cell technology for drug rescue, drug discovery and regenerative medicine, today announces that the Canadian Intellectual Property Office has issued a

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 08/13/14 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a stem cell company focused on drug rescue, drug discovery and regenerative medicine, announced today that will implement a 1-for-20 reverse split of its common stock effective at the opening of

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 06/16/14 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying pluripotent stem cell technology for drug rescue and regenerative medicine, today announces that the Canadian Intellectual Property Office has issued a Notice of

Industry-Led Consortium Developing a Novel Paradigm for Cardiac Safety Evaluation of New Drugs SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 05/22/14 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying pluripotent stem cell technology for drug rescue and regenerative

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/23/14 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying pluripotent stem cell technology for drug rescue and regenerative medicine, today announced that the United States Patent and Trademark Office has issued a Notice of

Collaboration Focused on Improving Cardiac Safety of Medical Products Based Upon Principles of FDA's Critical Path Initiative SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/10/14 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying pluripotent stem cell technology for drug